Echo IQ Limited (ASX:EIQ): Cardiac AI Commercialisation and Product Development

Aditi Sarkar

30 October 2026 10:22 PM AEDT

Echo IQ Limited (ASX:EIQ): Cardiac AI Commercialisation and Product Development

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

EchoSolv AS uses echocardiogram measurements to support assessment of structural heart disease.
The March 2026 quarter included more than 50 US accounts in stages of commercial engagement.
EchoSolv AS echocardiograms processed increased more than 130% QoQ in that quarter.
A June 2026 agreement addressed potential financing and distribution arrangements for the technology.
The half-year financial statements reported a loss of $8,659,669.

Echo IQ Limited develops artificial intelligence software that helps clinicians interpret echocardiographic measurements and assess structural heart disease. Its EchoSolv platform uses measurements already collected during routine heart ultrasound examinations rather than analysing the underlying images. In 2026, Echo IQ Limited (ASX:EIQ) reported developments in United States commercial engagement, software utilisation, clinical research and funding discussions.

United States Deployment and Software Utilisation

The company's March 2026 quarterly activities report described more than 50 active accounts proceeding through a structured sales process in the United States. The accounts were not all announced as contracted customers: the company distinguished early discussions from later stages such as proposals and contract negotiations. Echo IQ Limited (ASX:EIQ) also reported that the number of echocardiograms processed by EchoSolv AS had risen more than 130% quarter on quarter. This describes software usage, not the same thing as Revenue or completed hospital deployments.

Clinical Development Remains a Separate Workstream

EchoSolv AS focuses on decision support for aortic stenosis, a form of structural heart disease. Echo IQ's product materials describe software intended to complement, rather than replace, qualified clinical judgement. During the March quarter, management also discussed work on a heart failure application and supporting clinical evidence. Echo IQ Limited (ASX:EIQ) was preparing the potential regulatory pathway for EchoSolv HF, with additional clinical work forming part of the product programme. Progress in research, submissions and discussions must be distinguished from clearance, routine clinical adoption or recurring product income.

Proposed Financing and Reseller Arrangements

An official announcement dated 25 June 2026 described binding heads of agreement with a medical imaging technology company for a financing Facility and a related reseller arrangement. The stated aim was to assist the development and commercialisation of Echo IQ's AI software, including aortic stenosis and heart failure applications. However, the terms referred to definitive agreements still to be negotiated. For Echo IQ Limited (ASX:EIQ), the announcement therefore represented an important proposed commercial framework rather than proof that every contemplated arrangement had been completed on that date.

Financial Results and Operating Expenditure

For the half-year ended 31 December 2025, reported in February 2026, Echo IQ recorded revenue of $90,909 and a loss after tax of $8,659,669. The income statement also recorded consulting and professional fees, employee expenditure, Marketing costs and share-based payments. Those categories are relevant because software development, regulatory preparation and commercial deployment can require expenditure before meaningful sales revenue is recognised. Echo IQ Limited (ASX:EIQ) did not present commercial pipeline activity as equivalent to booked revenue.

How Commercial Progress Can Be Assessed

The company's disclosures identify several distinct milestones: the number of prospective customers entering procurement discussions, deployment of software within clinical workflows, processed study volumes, and development of additional applications. Echo IQ Limited (ASX:EIQ) measures these stages separately because each describes a different aspect of its operating activity. Increased utilisation provides evidence that the software is being used at participating sites, while signed commercial arrangements and future reported revenue would describe financial conversion. Regulatory status also varies by product and jurisdiction; the company's description of one application should not be extended to another without specific confirmation.

Key Insights

Echo IQ's 2026 disclosures link clinical software activity with a developing commercial operation. The key distinction is between engagement, utilisation, regulatory development and recognised revenue. Echo IQ Limited (ASX:EIQ) has reported measurable software usage and a pipeline of institutional discussions, while its half-year accounts show the financial cost of sustaining development and expansion.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.